Linked Life Data

9792152

Source:http://linkedlifedata.com/resource/pubmed/id/9792152

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1998-11-3
pubmed:abstractText
Transitional cell carcinomas may arise at any site within the urinary tract and are a source of considerable morbidity and mortality. In particular, patients with metastatic disease have a poor prognosis, with less than 5% alive at 5 years. A multicentre randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced or metastatic transitional cell carcinoma was conducted in the UK. From April 1991 to June 1995, 214 patients were entered by 16 centres, 108 randomized to CMV and 106 to MV. A total of 204 patients have died. The hazard ratio (relative risk of dying) was 0.68 (95% CI 0.51-0.90, P-value = 0.0065) in favour of CMV. This translates to an absolute improvement in 1-year survival of 13%, 16% in MV and 29% in CMV. The median survival for CMV and MV was 7 months and 4.5 months respectively. Two hundred and eight patients objectively progressed or died. The hazard ratio was 0.55 (95% CI 0.41-0.73, P-value = 0.0001) in favour of CMV. Two hundred and nine patients symptomatically progressed or died. The hazard ratio was 0.48 (95% CI 0.36-0.64, P-value = 0.0001) in favour of CMV. The most important pretreatment factors influencing overall survival were WHO performance status and extent of disease. These two factors were used to derive a prognostic index which could be used to categorize patients into three prognostic groups. We conclude that the addition of cisplatin to methotrexate and vinblastine should be considered in patients with transitional cell carcinoma, taking into account the increased toxicity.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-1244564, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-1520591, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-1607913, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-1960756, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-2189954, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-2746745, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-2819654, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-3343727, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-3550148, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-3981708, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-6347356, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-7525883, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-8932351, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-9053481, http://linkedlifedata.com/resource/pubmed/commentcorrection/9792152-9215826
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
78
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1067-75
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party.
pubmed:affiliation
Royal South Hants Hospital, Brintons Terrace, Southampton, UK.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Multicenter Study